Abstract: The technology relates in part to methods and systems for the identification of disease-associated transcript isoforms and peptides. In certain aspects, the technology relates to methods and systems for the identification of transcript isoforms and peptides preferentially expressed in tumor cells.

Abstract: Disclosed here are methods for treating a condition (e.g., cancer) with an appropriate immunotherapeutic agent and/or regimen. Also disclosed are methods for the use of effective combinations of proteins encoded by hot-spot mutations and/or tumor-associated mRNA splice variants to optimize the targeting of a patient's condition (e.g., cancer) with immunotherapies.

Abstract: Compositions and methods for treating solid and hematological cancers, including Acute Myeloid Leukemia (AML), are provided herein. The methods include administering truncated, dominant-negative, forms of Galectin-3.

Abstract: Compositions and methods for treating solid and hematological cancers, including Acute Myeloid Leukemia (AML), are provided herein. The methods include administering truncated, dominant-negative, forms of Galectin-3.

Abstract: A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells.

Abstract: Methods of identifying cancer/testes antigens (CTAs) useful as cancer treatment targets are disclosed and claimed herein. The methods include identifying human sperm proteins to which patients diagnosed with solid or hematological malignancies have established a humoral immune response.

Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

Abstract: This invention provides methods and compositions for diagnosis and treatment of ciliated hepatic foregut cysts (CHFC). In particular, the methods utilize one or more cancer-testis (CT) antigens as a marker for CHFC. The methods can involve the following steps: (a) obtaining a biological sample from a subject; (b) measuring the level of a CT antigen (or the level of the CT antigen nucleic acid such as mRNA or DNA) in the sample, and comparing the sample CT antigen level (or the level of the CT antigen nucleic acid such as mRNA or DNA) to the level in normal healthy subjects. A sample CT antigen (or its mRNA or DNA) level in excess of the level in normal healthy subjects indicates CHFC.

Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

Abstract: Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The Inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines. This hypothesis is supported by the expression of the sperm fibrous sheath protein, known as Sperm protein 17 (Sp17), which is detected in tumors of unrelated histological origin. It has the ability to induce T-cell based immune responses. The expression of the Sperm protein 17 (Sp17) in tumors of unrelated histological origin, and its' natural localization in the human sperm fibrous sheath (FS), led the Inventors to hypothesize that FS proteins might represent a new potential class of target antigens useful for developing cancer vaccines, as well as diagnostic and therapeutic treatments.

Abstract: The present invention includes compositions and methods for the diagnosis and treatment of lung cancer with a recombinant tumor-associated antigen loaded antigen presenting cell that generates a cytotoxic T lymphocyte specific immune response to at least one of SP17, AKAP-4, or PTTG1 expressed by one or more lung cancer cells.

Abstract: The methods and systems of the present invention provide for an expression vector containing a disease-specific promoter or a constitutive promoter linked to a gene encoding a therapeutic agent, such as a protein, microRNA, siRNA or other therapeutical molecule, e.g., other oligonucletide. The therapeutic agent may be, for example, Interleukin 10 (IL10), Forkhead box P3 (FOXP3), or a member of a transforming growth factor beta 1 (TGF?1) signaling pathway, such as SMAD3.

Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteasome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.

Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Gaicctin-3 and a proteasome inhibitor.

Abstract: The present invention provides a novel composition of matter useful for the treatment of neoplastic diseases. The novel composition is synergistic and comprised of galectin-3C in combination with a proteosome inhibitor, the combination having a pharmacologic activity greater than the expected additive effect of its individual components. Other embodiments of the invention provide novel synergistic compositions of galectin-3C with a proteasome inhibitor capable of reducing or overcoming resistance that develops to the proteasome inhibitor or reducing the adverse side effects from the proteasome inhibitor through increasing the therapeutic efficacy of lower doses.

Abstract: The present invention includes compositions and methods for treating a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell comprising: identifying a subject in need for treatment for a breast cancer cell, a metastatic breast cancer cell, or a triple negative breast cancer cell; and administering a therapeutically effective amount of a formulation that leads to the presentation of an immunogenic SP17 protein or peptide antigen on an antigen presenting cell to activate T cells that are SP17-specific T cells, wherein the SP17-specific T cells impair the growth of the breast cancer cell, the metastatic breast cancer cell, or the triple negative breast cancer cell growth.

Abstract: This invention provides methods and compositions for the treatment and/or prevention of cancer, including solid malignancies and hematologic malignancies. In particular, the present invention relates to immunotherapy using antigen-presenting cells loaded with tumor associated peptide antigens (TAPAs). If a subject expresses at least one tumor-associated antigen, the subject can be treated by antigen-presenting cells (e.g., dendritic cells) loaded with at least one tumor-associated peptide antigen derived from the tumor-associated antigen (s) expressed by the subject. This personalized immunotherapy induces or enhances immune responses to cells that express tumor-associated antigen(s).

Abstract: A method and composition for the diagnosis of and treatment of prostate cancer including a recombinant AKAP-4 tumor-associated antigen loaded antigen presenting cell that generates an AKAP-4 specific cytotoxic T lymphocyte specific for one or more prostate cancer cells.

Abstract: The present invention includes a method for the treatment of myeloma comprising identifying a patient with myeloma and administering to the patient a synergistic, effective amount of a truncated, dominant negative form of Galectin-3 and a proteasome inhibitor.